117 related articles for article (PubMed ID: 28136132)
21. Characterization of monkey cytochrome P450, P450 CMLd, responsible for S-mephenytoin 4-hydroxylation in hepatic microsomes of cynomolgus monkeys.
Ohmori S; Chiba K; Nakasa H; Horie T; Kitada M
Arch Biochem Biophys; 1994 Jun; 311(2):395-401. PubMed ID: 8203903
[TBL] [Abstract][Full Text] [Related]
22. Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model.
Steere B; Baker JA; Hall SD; Guo Y
Drug Metab Dispos; 2015 Jun; 43(6):870-83. PubMed ID: 25845826
[TBL] [Abstract][Full Text] [Related]
23. Cytochrome P450 1A1, 2C9, 2C19, and 3A4 Polymorphisms Account for Interindividual Variability of Toxicological Drug Metabolism in Cynomolgus Macaques.
Uno Y; Uehara S; Murayama N; Yamazaki H
Chem Res Toxicol; 2018 Dec; 31(12):1373-1381. PubMed ID: 30412386
[TBL] [Abstract][Full Text] [Related]
24. Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes.
Yoda N; Emoto C; Date S; Kondo S; Miyake M; Nakazato S; Umehara K; Kashiyama E
Xenobiotica; 2012 Aug; 42(8):719-30. PubMed ID: 22324396
[TBL] [Abstract][Full Text] [Related]
25. Assessment of multiple cytochrome P450 activities in metabolically inactivated human liver microsomes and roles of P450 2C isoforms in reaction phenotyping studies.
Murayama N; Yajima K; Hikawa M; Shimura K; Ishii Y; Takada M; Uno Y; Utoh M; Iwasaki K; Yamazaki H
Biopharm Drug Dispos; 2018 Feb; 39(2):116-121. PubMed ID: 29136681
[TBL] [Abstract][Full Text] [Related]
26. Purification and characterization of two forms of hepatic microsomal cytochrome P450 from untreated cynomolgus monkeys.
Ohmori S; Horie T; Guengerich FP; Kiuchi M; Kitada M
Arch Biochem Biophys; 1993 Sep; 305(2):405-13. PubMed ID: 8373178
[TBL] [Abstract][Full Text] [Related]
27. Human total clearance values and volumes of distribution of typical human cytochrome P450 2C9/19 substrates predicted by single-species allometric scaling using pharmacokinetic data sets from common marmosets genotyped for
Matsumoto S; Uehara S; Kamimura H; Ikeda H; Maeda S; Hattori M; Nishiwaki M; Kato K; Yamazaki H
Xenobiotica; 2021 Apr; 51(4):479-493. PubMed ID: 33455494
[TBL] [Abstract][Full Text] [Related]
28. Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation.
Lu C; Suri A; Shyu WC; Prakash S
Biopharm Drug Dispos; 2014 Dec; 35(9):543-52. PubMed ID: 25264242
[TBL] [Abstract][Full Text] [Related]
29. Purification from liver microsomes from untreated cynomolgus monkeys of cytochrome P450 closely related to human cytochrome P450 2B6.
Ohmori S; Shirakawa C; Motohashi K; Yoshida H; Abe H; Nakamura T; Horie T; Kitagawa H; Asaoka K; Rikihisa T
Mol Pharmacol; 1993 Feb; 43(2):183-90. PubMed ID: 8429823
[TBL] [Abstract][Full Text] [Related]
30. Development of a genotyping tool for a functionally relevant CYP2C19 allele (Phe100Asn, Ala103Val and Ile112Leu) in cynomolgus macaques.
Uno Y; Yamazaki H
J Vet Med Sci; 2016 Jan; 78(1):147-8. PubMed ID: 26300440
[TBL] [Abstract][Full Text] [Related]
31. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
Uno T; Sugimoto K; Sugawara K; Tateishi T
Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
[TBL] [Abstract][Full Text] [Related]
32. The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers.
Uno T; Sugimoto K; Sugawara K; Tateishi T
J Clin Pharm Ther; 2008 Feb; 33(1):67-73. PubMed ID: 18211619
[TBL] [Abstract][Full Text] [Related]
33. Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans.
Nishimuta H; Sato K; Mizuki Y; Yabuki M; Komuro S
Drug Metab Pharmacokinet; 2011 Jun; 26(3):300-6. PubMed ID: 21383522
[TBL] [Abstract][Full Text] [Related]
34. Hepatic, intestinal, renal, and plasma hydrolysis of prodrugs in human, cynomolgus monkey, dog, and rat: implications for in vitro-in vivo extrapolation of clearance of prodrugs.
Nishimuta H; Houston JB; Galetin A
Drug Metab Dispos; 2014 Sep; 42(9):1522-31. PubMed ID: 24994071
[TBL] [Abstract][Full Text] [Related]
35. Comparative study of the oxidation of propranolol enantiomers in hepatic and small intestinal microsomes from cynomolgus and marmoset monkeys.
Shimizudani T; Nagaoka K; Hanioka N; Yamano S; Narimatsu S
Chem Biol Interact; 2010 Jan; 183(1):67-78. PubMed ID: 19853591
[TBL] [Abstract][Full Text] [Related]
36. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
37. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol.
Obach RS
Drug Metab Dispos; 1997 Dec; 25(12):1359-69. PubMed ID: 9394025
[TBL] [Abstract][Full Text] [Related]
38. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
[TBL] [Abstract][Full Text] [Related]
39. Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19.
Jung F; Griffin KJ; Song W; Richardson TH; Yang M; Johnson EF
Biochemistry; 1998 Nov; 37(46):16270-9. PubMed ID: 9819219
[TBL] [Abstract][Full Text] [Related]
40. Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles.
Emoto C; Yoda N; Uno Y; Iwasaki K; Umehara K; Kashiyama E; Yamazaki H
Curr Drug Metab; 2013 Feb; 14(2):239-52. PubMed ID: 22963393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
